Lamotrigine injection - CyDex

Drug Profile

Lamotrigine injection - CyDex

Latest Information Update: 15 Sep 2014

Price : $50

At a glance

  • Originator CyDex Pharmaceuticals
  • Class Antiepileptic drugs; Small molecules; Triazines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Seizures

Most Recent Events

  • 09 Sep 2014 Preclinical trials in Seizures in USA (IM)
  • 09 Sep 2014 Preclinical trials in Seizures in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top